Synageva Biopharma (GEVA) Stock More Than Doubles to 52-Week High on Alexion Acquisition

NEW YORK (TheStreet) -- Shares of Synageva Biopharma  (GEVA) skyrocketed 125% to a 52-week high of $215.74 on Wednesday after Alexion Pharmaceuticals (ALXN) agreed to acquire it for $8.4 billion to widen Alexion's offering of rare disease treatments.

The cash-and-stock deal values Synageva at $230 a share based on Alexion's average closing price over the past nine days. This marks a 140% premium to Synageva's closing price of $95.87 on Tuesday.

Alexion agreed to pay $115 in cash and 0.6581 Alexion shares for every Synageva share.

The acquisition is an effort by Alexion to diversify from Soliris, the company's only marketed product. The company designed Soliris to treat two rare disorders: atypical hemolytic uremic syndrome and Paroxysmal nocturnal hemoglobinuria.

More than 10.1 million shares had changed hands as of 1:31 p.m., compared to the daily average volume of 1,241,030.

For more on this story, read Adam Feuerstein's in-depth coverage here.

GEVA Chart GEVA data by YCharts

More from Markets

US Stocks Gain, Yields Rise as Risk Appetite Returns Despite Trade War Salvos

US Stocks Gain, Yields Rise as Risk Appetite Returns Despite Trade War Salvos

What Is a Bear Market and What Does it Mean in 2018?

What Is a Bear Market and What Does it Mean in 2018?

Seaworld, Ex-CEO Settle With SEC; Keys to Alibaba Growth -- ICYMI

Seaworld, Ex-CEO Settle With SEC; Keys to Alibaba Growth -- ICYMI

The Products Behind the Smokin' Hot Tilray

The Products Behind the Smokin' Hot Tilray

Dow, Stocks Shrug Off Trade War Escalation, End Higher

Dow, Stocks Shrug Off Trade War Escalation, End Higher